Home Online Features U.S. FDA approves Celltrion's AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
Hand-out
Press Releases
Celltrion  
January 31, 2025

U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®

AVTOZMA® will be available as both intravenous (IV) and subcutaneous (SC) formulations with the same formulations and dosages as the reference productApproval was received for multiple indications, including rheumatoid arthritis

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social